Treats hypertension. ANDA 75116, held by Valeant Pharms North. Diltiazem Hydrochloride.
As of Nov 16, 2026, ANDA 75116 (Diltiazem Hydrochloride), held by Valeant Pharms North, was first approved by FDA on Dec 23, 1999, with 6 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Diltiazem Hydrochloride Extended-Release Capsules are indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive medications. Diltiazem Hydrochloride Extended-Release Capsules are indicated for the management of chronic stable angina and angina due to coronary artery spasm.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 23, 1999 | Original application | Approved |
| Diltiazem Hydrochloride120MG · capsule, extended release;oral | Diltiazem Hydrochloride | Rx |
| Diltiazem Hydrochloride180MG · capsule, extended release;oral | Diltiazem Hydrochloride | Rx |
| Diltiazem Hydrochloride240MG · capsule, extended release;oral | Diltiazem Hydrochloride | Rx |
| Diltiazem Hydrochloride300MG · capsule, extended release;oral | Diltiazem Hydrochloride | Rx |
| Aug 19, 2011 | Supplement 24Labeling | Approved | None posted |
| May 8, 2009 | Supplement 18Labeling | Approved | None posted |
| Oct 3, 2002 | Supplement 6Manufacturing | Approved | None posted |
| May 20, 2002 | Supplement 4Manufacturing | Approved | None posted |
| Apr 20, 2001 | Supplement 3Manufacturing | Approved | None posted |
| Oct 5, 2000 | Supplement 2Manufacturing | Approved | None posted |
| Dec 23, 1999 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters